Catalent And GlaxoSmithKline Extend Contractual Agreement

Catalent and GlaxoSmithKline Extend Contractual Agreement

Date: 09/24/2009

Somerset, NJ, September 24, 2009 — Catalent Pharma Solutions and GlaxoSmithKline (GSK) have agreed to extend their contractual relationship where Catalent will continue to supply GSK with its trade requirements of Lovaza® omega-3 acid ethyl esters in soft gelatin capsules. Lovaza is an omega-3 prescription medication derived from fish oil approved by the FDA to reduce very high triglycerides. The Lovaza softgels are manufactured in Catalent’s St. Petersburg, Florida facility, which is part of Catalent’s Oral Technologies segment.

“We value our long-term partnership with GSK and look forward to continuing that relationship,” said Dr. Aris Gennadios, Catalent’s Vice President and General Manager, Pharmaceutical Softgels.

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion in annual revenue. For more information, visit .

more products. better treatments. reliably supplied.™